Eddingpharm will continue to build up its pipeline through in-licensing and collaborating with global companies. While we focus on Respiratory, nephrology and cardiovascular disease areas, but we are also interested in other specialty areas with unmet medical needs in China. We will invest in clinical trials and manufacture of in-licensed products. Overall it reflects our on-going business transformation dedicated to growing our external R&D as a means to broaden our product portfolio.